Compare AISP & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISP | ELDN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 208.6M |
| IPO Year | N/A | 2014 |
| Metric | AISP | ELDN |
|---|---|---|
| Price | $2.66 | $2.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 492.5K | ★ 705.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $222.88 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $3.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.36 | $1.35 |
| 52 Week High | $7.20 | $4.60 |
| Indicator | AISP | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 69.96 |
| Support Level | $2.36 | $2.48 |
| Resistance Level | $3.92 | $2.77 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 47.33 | 92.31 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.